Director John W. Kozarich of Ligand Pharmaceuticals Inc (NASDAQ:LGND) executed the sale of 467 shares of the companys common stock on April 1, 2026. The aggregate proceeds from those dispositions were approximately $94,440, with transaction prices spanning from $199.9749 to $204.2627.
According to the filing, the trades were carried out pursuant to a pre-arranged trading plan that Kozarich adopted on March 7, 2025. After the April 1 transactions, Kozarichs direct ownership in Ligand stands at 42,253 shares.
The insider sale took place while Ligands shares were trading near $199.59. The stock has delivered a strong performance over the previous 12 months, returning 84% during that period.
Market analytics referenced in the filing note that, based on InvestingPro analysis, Ligand appears overvalued relative to its calculated Fair Value and is listed among companies designated as Most Overvalued. The filing also notes that subscribers can access additional InvestingPro Tips and a Pro Research Report for further analysis.
Financially, Ligand reported results for its fourth quarter that exceeded consensus expectations. The company posted adjusted earnings per share of $2.02 for the quarter versus a forecasted $1.49. Quarterly revenue totaled $59.7 million, ahead of the consensus estimate of $55.6 million.
For the full year, Liginds revenue reached $268 million, with core revenue at $240 million. Full-year adjusted EPS was reported at $8.13.
Analyst reactions included an action from Oppenheimer, which raised its price target for Ligand to $277 while maintaining an Outperform rating and citing a constructive view on the companys royalty revenue. Ligand disclosed fourth-quarter royalty revenue of $50.5 million, which aligned with Oppenheimers estimates. In addition, Stifel reiterated a Buy rating and kept a $230 price target on the shares.
The combination of an insider sale under a standing plan, a recent substantial run in the share price, an InvestingPro assessment of overvaluation, and a quarter that beat expectations - alongside continuing analyst support - frames the current market view of Ligand. The companys reported royalty revenue and the analyst commentary are central to recent investor attention.